BIM Stock Analysis: Biomerieux | PA
Diagnostics & Research | PA, France | Market Cap: 8.788m EUR | 12M Return: -40.1% | FR0013280286 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 10.3M
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
bioMérieux S.A. is a France-based company that develops, manufactures, and markets in vitro diagnostic (IVD) solutions, with a primary focus on infectious diseases. It sells its products worldwide and operates through two segments: Clinical Applications (serving medical and clinical laboratories) and Industrial Applications (serving food, pharmaceutical, and other industrial customers with microbiological quality-control testing). The company was founded in 1963, is headquartered in Marcy-lÉtoile, France, and operates as a subsidiary of Institut Mérieux SA.
Its product portfolio spans the full microbiology workflow, including chromogen culture media (CHROMID), automated blood culture systems (BACT/ALERT VIRTUO), multiplex and point-of-care PCR platforms (BIOFIRE and BIOFIRE SPOTFIRE), mass spectrometry identification (VITEK MS), automated and rapid antimicrobial susceptibility testing (VITEK 2, VITEK REVEAL, ETEST), and the VIDAS immunoassay line for markers such as sepsis. It also offers whole-genome sequencing tools (BIOMERIEUX EPISEQ CS), sample-preparation systems (EMAG, NUCLISENS), industrial pathogen detection kits (GENE-UP, VERIFLOW), and a software suite (Biomérieux Vision Suite) to support diagnostic and clinical decision-making.
BioMérieux sits within the global IVD industry, where the typical business model combines recurring reagent and consumable sales with installed-base instrument placements. The dual Clinical/Industrial structure is a distinguishing feature, as the industrial microbiology segment supplies quality-control testing to food, beverage, and cosmetics manufacturers, providing some diversification away from the more cyclical clinical diagnostics market.
- BIOFIRE multiplex PCR panel sales accelerate clinical segment growth
- Food safety regulation lifts industrial microbiology demand
- Dollar weakness pressures reported revenue from North American sales
| Net Income: 462.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 2.10 > 1.0 |
| NWC/Revenue: 36.78% < 20% (prev 44.97%; Δ -8.19% < -1%) |
| CFO/TA 0.16 > 3% & CFO 907.6m > Net Income 462.4m |
| Net Debt (-85.1m) to EBITDA (917.1m): -0.09 < 3 |
| Current Ratio: 2.30 > 1.5 & < 3 |
| Outstanding Shares: last quarter (118.4m) vs 12m ago -0.18% < -2% |
| Gross Margin: 52.04% > 18% (prev 55.64%; Δ -3.60% > 0.5%) |
| Asset Turnover: 72.16% > 50% (prev 52.71%; Δ 19.45% > 0%) |
| Interest Coverage Ratio: 30.27 > 6 (EBIT TTM 478.3m / Interest Expense TTM 15.8m) |
| A: 0.26 (Total Current Assets 2.60b - Total Current Liabilities 1.13b) / Total Assets 5.69b |
| B: 0.04 (Retained Earnings 226.1m / Total Assets 5.69b) |
| C: 0.09 (EBIT TTM 478.3m / Avg Total Assets 5.53b) |
| D: 3.08 (Book Value of Equity 4.30b / Total Liabilities 1.39b) |
| Altman-Z'' = 5.64 = AAA |
| DSRI: 0.99 (Receivables 962.1m/688.4m, Revenue 3.99b/2.83b) |
| GMI: 1.07 (GM 55.64% / 52.04%) |
| AQI: 0.87 (AQ_t 0.24 / AQ_t-1 0.28) |
| SGI: 1.41 (Revenue 3.99b / 2.83b) |
| TATA: -0.08 (NI 462.4m - CFO 907.6m) / TA 5.69b) |
| Beneish M = -2.76 (Cap -4..+1) = A |
As of August 24, 2026, the stock is trading at EUR 74.50 with a total of 119,894 shares traded. Over the past week, the price has changed by +1.92%, over one month by +7.97%, over three months by +1.99% and over the past year by -40.11%.
Current recommended Stop Loss: 72.30 (which is 3% or 1.3 ATR below the current price).
Biomerieux has no consensus analysts rating.
P/E Trailing = 19.1026
P/E Forward = 18.1818
P/S = 2.2021
P/B = 2.0432
P/EG = 1.8566
Revenue TTM = 3.99b EUR
EBIT TTM = 478.3m EUR
EBITDA TTM = 917.1m EUR
Long Term Debt = 211.3m EUR (from longTermDebt, last fiscal year)
Short Term Debt = 233.2m EUR (from shortTermDebt, last quarter)
Debt = 572.6m EUR (from shortLongTermDebtTotal, last quarter) + Leases 150.8m
Net Debt = -85.1m EUR (calculated: Debt 572.6m - CCE 657.7m)
Enterprise Value = 8.70b EUR (8.79b + Debt 572.6m - CCE 657.7m)
Interest Coverage Ratio = 30.27 (Ebit TTM 478.3m / Interest Expense TTM 15.8m)
EV/FCF = 14.86x (Enterprise Value 8.70b / FCF TTM 585.5m)
FCF Yield = 6.73% (FCF TTM 585.5m / Enterprise Value 8.70b)
FCF Margin = 14.67% (FCF TTM 585.5m / Revenue TTM 3.99b)
Net Margin = 11.59% (Net Income TTM 462.4m / Revenue TTM 3.99b)
Gross Margin = 52.04% ((Revenue TTM 3.99b - Cost of Revenue TTM 1.91b) / Revenue TTM)
Gross Margin QoQ = 55.18% (prev 49.00%)
Tobins Q-Ratio = 1.53 (Enterprise Value 8.70b / Total Assets 5.69b)
Interest Expense / Debt = 2.76% (Interest Expense 15.8m / Debt 572.6m)
Taxrate = 23.89% (145.0m / 607.0m)
NOPAT = 364.0m (EBIT 478.3m * (1 - 23.89%))
Current Ratio = 2.30 (Total Current Assets 2.60b / Total Current Liabilities 1.13b)
Debt / Equity = 0.13 (Debt 572.6m / totalStockholderEquity, last quarter 4.30b)
Debt / EBITDA = -0.09 (Net Debt -85.1m / EBITDA 917.1m)
Debt / FCF = -0.15 (Net Debt -85.1m / FCF TTM 585.5m)
Total Stockholder Equity = 4.13b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.36% (Net Income 462.4m / Total Assets 5.69b)
RoE = 11.18% (Net Income TTM 462.4m / Total Stockholder Equity 4.13b)
RoCE = 11.01% (EBIT 478.3m / Capital Employed (Equity 4.13b + L.T.Debt 211.3m))
RoIC = 7.91% (NOPAT 364.0m / Invested Capital 4.60b)
WACC = 6.06% (E(8.79b)/V(9.36b) * Re(6.32%) + D(572.6m)/V(9.36b) * Rd(2.76%) * (1-Tc(0.24)))
Discount Rate = 6.32% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -6.13 | Cagr: -0.05%
[DCF] Terminal Value 77.97% ; FCFF base≈527.1m ; Y1≈604.2m ; Y5≈889.2m
[DCF] Fair Price = 114.2 (EV 13.4b - Net Debt -85.1m = Equity 13.5b / Shares 118.0m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: N/A | # QB: 0
Revenue Correlation: 9.04 | Revenue CAGR: 1.68% | SUE: 1.12 | # QB: 1
EPS current Quarter (2026-03-31): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS next Quarter (2026-06-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS current Year (2026-12-31): EPS=4.34 | Chg30d=-0.06% | Revisions=-21% | GrowthEPS=-6.4% | GrowthRev=+1.3%
EPS next Year (2027-12-31): EPS=4.66 | Chg30d=-3.84% | Revisions=-53% | GrowthEPS=+7.4% | GrowthRev=+5.2%
[Analyst] Revisions Ratio: -42% (up=6, down=17)